MapLight Therapeutics, Inc.
corporate_fare Company Profile
MapLight Therapeutics, Inc. (NASDAQ:MPLT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for MPLT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for MPLT spans 10-Q, 8-K, 4, SCHEDULE 13D/A.
Recent high-impact activity:
- MapLight 10-Q Confirms $51.6M Q3 Loss, $463.4M Cash Through 2028
- MapLight Posts $51.6M Q3 Loss, $463.4M Cash Through 2028
- MapLight Posts 97-Cent Quarterly Loss as Cash Burn Continues
- Catalyst4 Boosts MapLight Stake with $83.4M Open-Market Purchase
- Catalyst4 Discloses $83.4M PIPE Stake, Now Controls 49.9% of MapLight
Financial Snapshot
Short Interest & Short Volume
10.31 days to coverFINRA reported short interest of 3,251,647 shares in MPLT as of the October 30, 2026 settlement, a 2.1% decrease from the prior period — about 10.3 days to cover at its recent average daily volume. On November 20, 2026, 45.4% of MPLT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for MPLT, detected from its recent SEC filings · based on capital-structure filings through 2026-11-16.
New $400M Shelf Registration · New $100M ATM With Leerink
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →